BRAF mutational epidemiology in dysplastic nevi: Does different solar UV radiation exposure matter?

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 5, 2014, Pages 615-625

  Saroufim, M ^a   Novy, M ^b   Taraif, S ^c   Habib, R H ^a   Loya, A ^d   Rauscher, B ^b   Kriegshauser G ^b   Oberkanins, C ^b   Khalifeh, I ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b VIENNALAB DIAGNOSTICS GMBH   (Austria)

^c SAAD SPECIALIST HOSPITAL   (Saudi Arabia)

^d Shaukat Khanum Cancer Memorial Hospital and Research Centre   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ADULT; ARTICLE; DYSPLASIA; DYSPLASTIC NEVUS; FEMALE; GENE MUTATION; HUMAN; LEBANON; MAJOR CLINICAL STUDY; MALE; MELANOCYTE; MUTATION RATE; PREDICTION; PRIORITY JOURNAL; RADIATION EXPOSURE; SAUDI ARABIA; SOLAR RADIATION; SOMATIC MUTATION; STRATUM CORNEUM; ULTRAVIOLET RADIATION; DYSPLASTIC NEVUS SYNDROME; GENETICS; MOLECULAR EPIDEMIOLOGY; MUTATION; OCCUPATIONAL EXPOSURE; SUNLIGHT;

ADULT; DYSPLASTIC NEVUS SYNDROME; FEMALE; HUMANS; MALE; MOLECULAR EPIDEMIOLOGY; MUTATION; OCCUPATIONAL EXPOSURE; PROTO-ONCOGENE PROTEINS B-RAF; SUNLIGHT;

EID: 84899485568     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12148     Document Type: Article

References (47)

1. Hussein MR,. Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues. J Clin Pathol 2005; 58: 453-456.
2. Halpern AC, Guerry Dt, Elder DE, et al,. Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study. Arch Dermatol 1991; 127: 995-999.
3. Marghoob AA, Kopf AW, Rigel DS, et al,. Risk of cutaneous malignant melanoma in patients with 'classic' atypical-mole syndrome. A case-control study. Arch Dermatol 1994; 130: 993-998.
4. Bataille V, Bishop JA, Sasieni P, et al,. Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br J Cancer 1996; 73: 1605-1611.
5. Carey WP Jr, Thompson CJ, Synnestvedt M, et al,. Dysplastic nevi as a melanoma risk factor in patients with familial melanoma. Cancer 1994; 74: 3118-3125.
6. Tucker MA, Halpern A, Holly EA, et al,. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997; 277: 1439-1444.
7. Sober AJ, Burstein JM,. Precursors to skin cancer. Cancer 1995; 75 (2 Suppl): 645-650.
8. Seykora J, Elder D,. Dysplastic nevi and other risk markers for melanoma. Semin Oncol 1996; 23: 682-687.
9. Davies H, Bignell GR, Cox C, et al,. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
10. Peyssonnaux C, Eychene A,. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001; 93: 53-62.
11. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR,. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008; 132: 363-374.
12. Pollock PM, Harper UL, Hansen KS, et al,. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33: 19-20.
13. Poynter JN, Elder JT, Fullen DR, et al,. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 2006; 16: 267-273.
14. Bennett DC,. Human melanocyte senescence and melanoma susceptibility genes. Oncogene 2003; 22: 3063-3069.
15. Elwood JM, Jopson J,. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997; 73: 198-203.
16. Gilchrest BA, Eller MS, Geller AC, Yaar M,. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999; 340: 1341-1348.
17. Tsao H, Sober AJ,. Ultraviolet radiation and malignant melanoma. Clin Dermatol 1998; 16: 67-73.
18. Gandini S, Sera F, Cattaruzza MS, et al,. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005; 41: 2040-2059.
19. Bauer J, Buttner P, Wiecker TS, Luther H, Garbe C,. Risk factors of incident melanocytic nevi: a longitudinal study in a cohort of 1,232 young German children. Int J Cancer 2005; 115: 121-126.
20. Sarasin A,. The molecular pathways of ultraviolet-induced carcinogenesis. Mutat Res 1999; 428: 5-10.
21. Sasaki Y, Niu C, Makino R, et al,. BRAF point mutations in primary melanoma show different prevalences by subtype. J Invest Dermatol 2004; 123: 177-183.
22. Liu W, Kelly JW, Trivett M, et al,. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol 2007; 127: 900-905.
23. Akslen LA, Puntervoll H, Bachmann IM, et al,. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res 2008; 18: 29-35.
24. Ichii-Nakato N, Takata M, Takayanagi S, et al,. High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi. J Invest Dermatol 2006; 126: 2111-2118.
25. Wu J, Rosenbaum E, Begum S, Westra WH,. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis. Am J Dermatopathol 2007; 29: 534-537.
26. Decarlo K, Yang S, Emley A, Wajapeyee N, Green M, Mahalingam M,. Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7-challenging the concept of dysplastic nevi as precursor lesions? Hum Pathol 2010; 41: 886-894.
27. Lee-Taylor J, Madronich S, Fischer C, Mayer B,. A climatology of UV radiation, 1979-2000. UV Radiation in Global Climate Change: Measurements, Modeling and Effects on Ecosystems. 2010; 1-20.
28. Broekaert SM, Roy R, Okamoto I, et al,. Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res 2010; 23: 763-770.
29. Shea CR, Vollmer RT, Prieto VG,. Correlating architectural disorder and cytologic atypia in Clark (dysplastic) melanocytic nevi. Hum Pathol 1999; 30: 500-505.
30. Viros A, Fridlyand J, Bauer J, et al,. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 2008; 5: e120.
31. Oberkanins C, Moritz A, de Villiers JN, Kotze MJ, Kury F,. A reverse-hybridization assay for the rapid and simultaneous detection of nine HFE gene mutations. Genet Test 2000; 4: 121-124.
32. Ausch C, Buxhofer-Ausch V, Oberkanins C, et al,. Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization. J Mol Diagn 2009; 11: 508-513.
33. Heakal Y, Kester M, Savage S,. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. Ann Pharmacother 2011; 45: 1399-1405.
34. Papp T, Schipper H, Kumar K, Schiffmann D, Zimmermann R,. Mutational analysis of the BRAF gene in human congenital and dysplastic melanocytic naevi. Melanoma Res 2005; 15: 401-407.
35. Yazdi AS, Palmedo G, Flaig MJ, et al,. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 2003; 121: 1160-1162.
36. Thomas NE,. BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res 2006; 16: 97-103.
37. Uribe P, Wistuba II, Gonzalez S,. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol 2003; 25: 365-370.
38. Uribe P, Andrade L, Gonzalez S,. Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. J Invest Dermatol 2006; 126: 161-166.
39. Clark WH Jr, Tucker MA,. Problems with lesions related to the development of malignant melanoma: common nevi, dysplastic nevi, malignant melanoma in situ, and radial growth phase malignant melanoma. Hum Pathol 1998; 29: 8-14.
40. Clark WH Jr,. Reimer RR, Greene M, Ainsworth AM, Mastrangelo MJ. Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol 1978; 114: 732-738.
41. van Elsas A, Zerp SF, van der Flier S, et al,. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 1996; 149: 883-893.
42. Van der Lubbe JL, Rosdorff HJ, Bos JL, Van der Eb AJ,. Activation of N-ras induced by ultraviolet irradiation in vitro. Oncogene Res 1988; 3: 9-20.
43. Pierceall WE, Kripke ML, Ananthaswamy HN,. N-ras mutation in ultraviolet radiation-induced murine skin cancers. Cancer Res 1992; 52: 3946-3951.
44. Maldonado JL, Fridlyand J, Patel H, et al,. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003; 95: 1878-1890.
45. Miller CJ, Cheung M, Sharma A, et al,. Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms. J Invest Dermatol 2004; 123: 990-992.
46. Turner DJ, Zirvi MA, Barany F, Elenitsas R, Seykora J,. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction. J Cutan Pathol 2005; 32: 334-339.
47. Arumi-Uria M, McNutt NS, Finnerty B,. Grading of atypia in nevi: correlation with melanoma risk. Mod Pathol 2003; 16: 764-771.